DDInter1042 DDInter1214
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors . It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents.
Midostaurin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Midostaurin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Midostaurin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Saxagliptin
Midostaurin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Midostaurin {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Midostaurin {u} may lead to a major life threatening interaction when taken with {v} Crizotinib
Midostaurin may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Midostaurin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Midostaurin may lead to a major life threatening interaction when taken with Leflunomide
Midostaurin may lead to a major life threatening interaction when taken with Crizotinib